Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

A phase II clinical trial with single-agent decitabine was conducted in older patients (≥60 years) with previously untreated acute myeloid leukemia (AML) who were not candidates for or who refused intensive chemotherapy. Subjects received low-dose decitabine at 20 mg/m(2) i.v. over 1 h on days 1 to...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Blum, William, Garzon, Ramiro, Klisovic, Rebecca B., Schwind, Sebastian, Walker, Alison, Geyer, Susan, Liu, Shujun, Havelange, Violaine, Becker, Heiko, Schaaf, Larry, Mickle, Jon, Devine, Hollie, Kefauver, Cheryl, Devine, Steven M., Chan, Kenneth K., Heerema, Nyla A., Bloomfield, Clara D., Grever, Michael R., Byrd, John C., Villalona-Calero, Miguel, Croce, Carlo M., Marcucci, Guido
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: National Academy of Sciences 2010
Aiheet:
Biological Sciences
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2867720/
https://ncbi.nlm.nih.gov/pubmed/20368434
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1002650107
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia